Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies is underpinned by clonoSEQ’s dominant position in the FDA-cleared MRD market, reinforced by NCCN guideline language that should shift the test from “nice to have” toward standard of care in multiple myeloma and broaden use across additional indications. The business is also seeing powerful operating momentum, with Q2’26 MRD volumes up 43% Y/Y, ASPs at $1,382/test, 71% gross margins, and 2026 MRD revenue guidance raised to $268M-$278M alongside expectations for 38%-40% volume growth. A planned separation of the profitable core MRD segment from the non-core immune medicine business, combined with strong reimbursement, EMR integrations, and growing blood-based testing adoption, creates a clear value-unlock narrative.

Adaptive Biotechnologies is facing a fragile outlook because investor sentiment appears heavily dependent on continued record growth in its MRD franchise, and any miss on that metric could quickly pressure the stock. The company also trades at a significant premium multiple, leaving little room for execution stumbles while reimbursement, clinical guideline adoption, regulatory hurdles, and slower customer uptake could constrain clonoSEQ growth. More broadly, exposure to volatile specialty diagnostics pricing, macro weakness, and the risk that revenue momentum does not translate into durable profitability support a negative fundamental view.